Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection
Authors:
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 54, 128432
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current EvidenceDrug Design, Development and Therapy, 2019
- The Continuing Threat of Methicillin-Resistant Staphylococcus aureusAntibiotics, 2019
- The Concept of an Ideal Antibiotic: Implications for Drug DesignMolecules, 2019
- Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult SubjectsAntimicrobial Agents and Chemotherapy, 2018
- A Chiral Benzoquinolizine-2-carboxylic Acid Arginine Salt Active against Vancomycin-Resistant Staphylococcus aureusJournal of Medicinal Chemistry, 2005
- Activity of the new quinolone WCK 771 against pneumococciClinical Microbiology and Infection, 2005
- Oral bioavailability of trovafloxacin with and without food in healthy volunteersJournal of Antimicrobial Chemotherapy, 1997
- A Practical Synthesis of (S)-(-)-Nadifloxacin: Novel Acid-Catalyzed Racemization of Tetrahydroquinaldine Derivative.Chemical and Pharmaceutical Bulletin, 1996
- Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgarisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: A double-blind group comparison study versus cream baseJournal of the American Academy of Dermatology, 1991